个人中心 - 老虎社区

6c14f57b

Learn nothing be free

IP属地：未知

帖子 · 8帖子 · 8
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 6c14f57b6c14f57b
  ·2021-06-22
  Xrp i think will moon
  10, 30-year Treasury yields recover overnight dip to stage solid post-Fed climb Monday
  Yields for benchmark bonds on Monday climb higher on the long-end for the curve, with the long bond
  10, 30-year Treasury yields recover overnight dip to stage solid post-Fed climb Monday
  107 评论
  1
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Daftpunk better
  非常抱歉，此主贴已删除
  213 评论
  点赞
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Fake
  非常抱歉，此主贴已删除
  205 评论
  3
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Nice
  If You Thought These 2 Big Nasdaq Winners Were Done, Think Again
  On a strong day for the Nasdaq, two highfliers stood out. Volatility has returned to the stock mark
  If You Thought These 2 Big Nasdaq Winners Were Done, Think Again
  161 评论
  点赞
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  I thikk no leh
  The Fed Has Spoken: Stocks To Buy Now
  Summary The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing o
  The Fed Has Spoken: Stocks To Buy Now
  126 评论
  1
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Xrp to the moon
  非常抱歉，此主贴已删除
  146 评论
  点赞
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Lklpx
  These 3 Dow Stocks Are Set to Soar in 2021's Second Half
  Here are the companies investors are most excited about -- and why.
  These 3 Dow Stocks Are Set to Soar in 2021's Second Half
  266 评论
  2
  分享
  举报
- 6c14f57b6c14f57b
  ·2021-06-22
  Hi! I truly xrp to the moon and i am allIn what about you?
  220 评论
  点赞
  分享
  举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

老虎社区侵权投诉指引

中国互联网举报中心·北京互联网举报中心

网络谣言曝光台·扫黄打非举报中心

网络110报警服务

© 2018-2024 老虎社区版权所有

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

qrcode

关注我们

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3586344416928957","uuid":"3586344416928957","gmtCreate":1623250965476,"gmtModify":1624360683199,"name":"6c14f57b","pinyin":"kahsiang","introduction":"","introductionEn":"","signature":"Learn nothing be free","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":4,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":129389626,"gmtCreate":1624359293065,"gmtModify":1634007337438,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Xrp i think will moon","listText":"Xrp i think will moon","text":"Xrp i think will moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129389626","repostId":"2145803031","repostType":4,"repost":{"id":"2145803031","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1624344420,"share":"https://www.laohu8.com/m/news/2145803031?lang=&edition=full","pubTime":"2021-06-22 14:47","market":"us","language":"en","title":"10, 30-year Treasury yields recover overnight dip to stage solid post-Fed climb Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2145803031","media":"Dow Jones","summary":"Yields for benchmark bonds on Monday climb higher on the long-end for the curve, with the long bond ","content":"<p>Yields for benchmark bonds on Monday climb higher on the long-end for the curve, with the long bond notching its sharpest yield climb since March. The moves come as investors continue to position following a Federal Reserve update last week that was interpreted as more inclined to end pandemic-era accommodations sooner than later, even as the central bank views surging pricing pressures as likely to be short-lived.</p>\n<p><b>How Treasurys performed</b></p>\n<p>Fixed-income drivers</p>\n<p>Strategists didn't offer an clear reason why yields turned lower and then popped up, but some attribute it to bearish positioning, with investors forced to unwind bets that prices would head lower, pushing yields higher.</p>\n<p>Read:Markets are sending 'peculiar' signals as Fed changes tune--here's what they mean</p>\n<p>In theory, the Fed's stance that post-COVID inflation pressures should be short-lived and the expectation that the Fed could begin raising rates as early as late 2022 or early 2023, should be nudging yields higher.</p>\n<p>But bond yields, which move opposite to prices, have been reluctant to hold higher for an extended period in benchmark 30-year and 10-year Treasurys, which are used to price everything from mortgages to corporate bonds.</p>\n<p>On Monday, both St. Louis Fed President James Bullard and Dallas Fed President Rob Kaplan said they expect the pace of inflation next year to remain above the central bank's target.</p>\n<p>Last Friday, Bullard, in interview with CNBC, suggested that he would be inclined to see the Fed lift interest rates by late 2022 and said that Fed Chairman Jerome Powell has effectively opened the door to tapering the central bank's monthly purchases of $120 billion in Treasurys and mortgage-backed securities.</p>\n<p>The market will hear from Powell again on Tuesday when he testifies before the House select subcommittee on the impact of the coronavirus on the economy.</p>\n<p><b>What strategists said</b></p>\n<p>Inflation-themed \"trades such as a bear-steepening of the curve and a weaker dollar depend on the Fed remaining dovish, with the implication that a hawkish Fed would move markets in reverse,\" wrote Alex Pelle and Steven Ricchiuto, U.S. economists at Mizuho, in an afternoon note.</p>\n<p>\"Our view is that Powell remains solidly on the dovish end of the FOMC, but he is a Chair trying to manage an increasingly factious committee as incoming inflation data surprises to the upside.\"</p>\n<p>Still, the trajectory of monetary, including any pullback, will hinge on the labor market recovery, the team wrote, adding that with the \"realistic unemployment rate closer to 7.9%,\" realizing the \"gargantuan task\" of a 4.5% unemployment rate by year-end would be difficult and \"require job growth averaging around 900K job additions per month for the next 6 months.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10, 30-year Treasury yields recover overnight dip to stage solid post-Fed climb Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10, 30-year Treasury yields recover overnight dip to stage solid post-Fed climb Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-22 14:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yields for benchmark bonds on Monday climb higher on the long-end for the curve, with the long bond notching its sharpest yield climb since March. The moves come as investors continue to position following a Federal Reserve update last week that was interpreted as more inclined to end pandemic-era accommodations sooner than later, even as the central bank views surging pricing pressures as likely to be short-lived.</p>\n<p><b>How Treasurys performed</b></p>\n<p>Fixed-income drivers</p>\n<p>Strategists didn't offer an clear reason why yields turned lower and then popped up, but some attribute it to bearish positioning, with investors forced to unwind bets that prices would head lower, pushing yields higher.</p>\n<p>Read:Markets are sending 'peculiar' signals as Fed changes tune--here's what they mean</p>\n<p>In theory, the Fed's stance that post-COVID inflation pressures should be short-lived and the expectation that the Fed could begin raising rates as early as late 2022 or early 2023, should be nudging yields higher.</p>\n<p>But bond yields, which move opposite to prices, have been reluctant to hold higher for an extended period in benchmark 30-year and 10-year Treasurys, which are used to price everything from mortgages to corporate bonds.</p>\n<p>On Monday, both St. Louis Fed President James Bullard and Dallas Fed President Rob Kaplan said they expect the pace of inflation next year to remain above the central bank's target.</p>\n<p>Last Friday, Bullard, in interview with CNBC, suggested that he would be inclined to see the Fed lift interest rates by late 2022 and said that Fed Chairman Jerome Powell has effectively opened the door to tapering the central bank's monthly purchases of $120 billion in Treasurys and mortgage-backed securities.</p>\n<p>The market will hear from Powell again on Tuesday when he testifies before the House select subcommittee on the impact of the coronavirus on the economy.</p>\n<p><b>What strategists said</b></p>\n<p>Inflation-themed \"trades such as a bear-steepening of the curve and a weaker dollar depend on the Fed remaining dovish, with the implication that a hawkish Fed would move markets in reverse,\" wrote Alex Pelle and Steven Ricchiuto, U.S. economists at Mizuho, in an afternoon note.</p>\n<p>\"Our view is that Powell remains solidly on the dovish end of the FOMC, but he is a Chair trying to manage an increasingly factious committee as incoming inflation data surprises to the upside.\"</p>\n<p>Still, the trajectory of monetary, including any pullback, will hinge on the labor market recovery, the team wrote, adding that with the \"realistic unemployment rate closer to 7.9%,\" realizing the \"gargantuan task\" of a 4.5% unemployment rate by year-end would be difficult and \"require job growth averaging around 900K job additions per month for the next 6 months.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","SPY":"标普500ETF",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145803031","content_text":"Yields for benchmark bonds on Monday climb higher on the long-end for the curve, with the long bond notching its sharpest yield climb since March. The moves come as investors continue to position following a Federal Reserve update last week that was interpreted as more inclined to end pandemic-era accommodations sooner than later, even as the central bank views surging pricing pressures as likely to be short-lived.\nHow Treasurys performed\nFixed-income drivers\nStrategists didn't offer an clear reason why yields turned lower and then popped up, but some attribute it to bearish positioning, with investors forced to unwind bets that prices would head lower, pushing yields higher.\nRead:Markets are sending 'peculiar' signals as Fed changes tune--here's what they mean\nIn theory, the Fed's stance that post-COVID inflation pressures should be short-lived and the expectation that the Fed could begin raising rates as early as late 2022 or early 2023, should be nudging yields higher.\nBut bond yields, which move opposite to prices, have been reluctant to hold higher for an extended period in benchmark 30-year and 10-year Treasurys, which are used to price everything from mortgages to corporate bonds.\nOn Monday, both St. Louis Fed President James Bullard and Dallas Fed President Rob Kaplan said they expect the pace of inflation next year to remain above the central bank's target.\nLast Friday, Bullard, in interview with CNBC, suggested that he would be inclined to see the Fed lift interest rates by late 2022 and said that Fed Chairman Jerome Powell has effectively opened the door to tapering the central bank's monthly purchases of $120 billion in Treasurys and mortgage-backed securities.\nThe market will hear from Powell again on Tuesday when he testifies before the House select subcommittee on the impact of the coronavirus on the economy.\nWhat strategists said\nInflation-themed \"trades such as a bear-steepening of the curve and a weaker dollar depend on the Fed remaining dovish, with the implication that a hawkish Fed would move markets in reverse,\" wrote Alex Pelle and Steven Ricchiuto, U.S. economists at Mizuho, in an afternoon note.\n\"Our view is that Powell remains solidly on the dovish end of the FOMC, but he is a Chair trying to manage an increasingly factious committee as incoming inflation data surprises to the upside.\"\nStill, the trajectory of monetary, including any pullback, will hinge on the labor market recovery, the team wrote, adding that with the \"realistic unemployment rate closer to 7.9%,\" realizing the \"gargantuan task\" of a 4.5% unemployment rate by year-end would be difficult and \"require job growth averaging around 900K job additions per month for the next 6 months.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":107,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129389358,"gmtCreate":1624359277674,"gmtModify":1634007337660,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Daftpunk better","listText":"Daftpunk better","text":"Daftpunk better","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129389358","repostId":"1139414035","repostType":4,"isVote":1,"tweetType":1,"viewCount":213,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129380233,"gmtCreate":1624359259622,"gmtModify":1634007338025,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Fake","listText":"Fake","text":"Fake","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129380233","repostId":"1177499959","repostType":4,"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129380832,"gmtCreate":1624359246026,"gmtModify":1634007338147,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129380832","repostId":"1186855284","repostType":4,"repost":{"id":"1186855284","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<blockquote>\n On a strong day for the Nasdaq, two highfliers stood out.\n</blockquote>\n<p>Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p>\n<p>It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p>\n<p><b>More moves for Moderna and BioNTech</b></p>\n<p>Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p>\n<p>The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p>\n<p>In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p>\n<p>More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p>\n<p><b>Will existing vaccines be enough?</b></p>\n<p>The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p>\n<p>For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p>\n<p>If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 14:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq  was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129316188,"gmtCreate":1624358845344,"gmtModify":1634007342370,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"I thikk no leh","listText":"I thikk no leh","text":"I thikk no leh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129316188","repostId":"1124495234","repostType":4,"repost":{"id":"1124495234","pubTimestamp":1624352353,"share":"https://www.laohu8.com/m/news/1124495234?lang=&edition=full","pubTime":"2021-06-22 16:59","market":"us","language":"en","title":"The Fed Has Spoken: Stocks To Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1124495234","media":"seekingalpha","summary":"Summary\n\nThe Fed could begin raising rates sooner than 2023.\nHealthcare and utilities are climbing o","content":"<p><b>Summary</b></p>\n<ul>\n <li>The Fed could begin raising rates sooner than 2023.</li>\n <li>Healthcare and utilities are climbing our sector ranking.</li>\n <li>The top stocks in our universe today.</li>\n</ul>\n<p>As I wrote last week,inflation is here. Earlier this week, the Federal Reserve's Federal Open Market Committee made its most significant hawkish shift yet, accelerating its timeline for hiking the Federal Funds rate to 2023 from 2024 and setting the table to end asset repurchases as soon as this year.</p>\n<p>The Central Bank left little doubt government's one-two monetary and fiscal punch has reinvigorated economic activity. Exiting the meeting, bankers believe gross domestic product, or GDP, willgrow 7%this year, up from its 6.5% forecast in March, resulting in core inflation of 3%, up from its prior outlook for 2.2%.</p>\n<p>Historically, the Federal Reserve has a reputation for under estimating inflationary pressure, forcing it to act more quickly and aggressively than it originally signals. Whether this means the Fed is behind the inflationary curve now is anyone's guess, but if it is, then we may see an even more hawkish tone over the coming year.</p>\n<p>For now, the Federal Reserve's stance has sparked a tug-of-war between those arguing rate hikes are too far off in the future to worry of a slowdown and those believing the Fed's timeline is still too optimistic. The knee-jerk reaction to its announcement was to buy speculative stocks, including technology, and sell mid-cycle stocks, such as energy. Further confusing the matter, late-cycle baskets, including healthcare and utilities, made the biggest move up in our large-cap sector ranking this week (see below), suggesting we may be closer to an economic reckoning than originally thought.</p>\n<p><b>The best sectors today</b></p>\n<p>Weekly, we rank 1,600 institutional-quality stocks across seven factors. In short, our scoring system incorporates earnings growth, earnings beats, insider buying, short- and long-term money flows, days to cover held short, trends in valuation, and seasonality.</p>\n<p>Once stocks run our gauntlet, we aggregate individual scores by sector to gain insight into the best baskets to over- or under-weight.</p>\n<p>Previously, I've written abouttechnology's relative weaknessin our ranking. The sector still scores below our average universe score, despite catching bids earlier this week. It will be interesting to see if this week's buying spree continues, helping technology climb our ranking, especially since technology doesn't normally score below average for long. For now, staying industry and stock specific in technology still appears to be the best bet.</p>\n<p><img src=\"https://static.tigerbbs.com/5d6585be1d6bfa0b5a61dc98f0ca8c85\" tg-width=\"623\" tg-height=\"421\" referrerpolicy=\"no-referrer\"><i>Source: Top Stocks for Tomorrow.</i></p>\n<p>We also break out our sector scores by market cap every week.</p>\n<p>Often, sectors move up or down in our large-cap ranking sooner than they do in mid cap or small cap; giving investors an early signal of shifting tides. For this reason, paying close attention to the large cap ranking can pay off even if you invest in smaller companies.</p>\n<p>This week, both healthcare and utilities moved up in our large-cap ranking. The improvement could reflect growing clarity into the groups because of the Supreme Court's decision to keep the Affordable Care Act in place and energy strains in Texas, California, and elsewhere, respectively. Perhaps, the move up in these baskets, which are relatively inelastic to economic activity, signals the first Fed Funds rate hike will happen in 2022, not 2023, though.</p>\n<p>Overall, REITs, healthcare, energy, utilities, and financials are top rated in large cap, while technology, consumer goods, and basics score below average. In mid cap, energy, REITs, utilities, and consumer goods are best, while technology, industrials, basics, and healthcare are low scoring. The top small cap sectors are REITs, energy, financials, and services and the lowest-scoring baskets are healthcare, technology, and basics. Focusing on stocks in top-scoring sectors and staying selective in low-scoring sectors could be the best way to find alpha from here.</p>\n<p><img src=\"https://static.tigerbbs.com/440717f3f07f728c62361601e338f285\" tg-width=\"640\" tg-height=\"209\" referrerpolicy=\"no-referrer\"><i>Source: Top Stocks for Tomorrow.</i></p>\n<p><b>The strongest scoring stocks to buy</b></p>\n<p>As I mentioned, we score stocks in our universe weekly, allowing us to rank them from best to worst by screening criteria, such as market cap and sector. For example, the following stock ideas come from our weekly report highlighting the highest-scoring stocks in our universe by sector, regardless of market cap.</p>\n<p>Over 200 stocks made the cut for this report, including the following nine stocks.</p>\n<p>First up, investors ought to think about pharmaceutical stocks given large-cap healthcare is improving in our sector work. Over 20 healthcare stocks made our best stocks list this week, including AbbVie(NYSE:ABBV)and Bristol-Myers Squibb (BMY).</p>\n<p>In the U.S., AbbVie faces-off against generic versions of its mega-blockbuster immunology drug, Humira, in 2023, but up-and-coming top sellers, including Rinvoq and Skyrizi, should helpinsulate it against a drop-off in sales. Botox also provides a nice revenue tailwind because aesthetics demand isalready above pre-COVID levelsthanks to post-vaccination doctor visits. Moonshot-style data is coming soon, too, with trial results in Alzheimer's anticipated this summer and pivotal results from Vraylar's major depressive disorder trials later this year. Finally, since it's paying down debt and still guiding for high single-digit sales growth from 2025 to 2029, despite Humira's loss of exclusivity, its 4.5% dividend appears to be on solid ground.</p>\n<p>Improving post-vaccination trends may make it time to watch Bristol-Myers, too. It's heavily exposed to cancer indications through it's top-selling Opdivo and Yervoy, and earlier this month, managementsaidCOVID-era, double-digit declines in new patient starts for oncology drugs improved to a 5% to 10% decline. If trends continue improving, then oncology drug demand could be back to a pre-COVID levels soon. Similarly, rebounding doctor visits also support sales of Bristol-Myers' Eliquis, a blockbuster oral anticoagulant used in cardiovascular disease.</p>\n<p>Outside of healthcare, energy stocks could make sense given increasing global GDP and inflation forecasts. Oil stocks sold off following the Fed's update last week, however, measured production growth should help keep per barrel prices high at E&amp;P companies, including Hess Corp (HES), while also providing demand tailwinds for services providers, including Oceaneering International (OII).</p>\n<p>Hess Corp'scollaborationoffshore Guyana with Exxon Mobil (XOM) gives it 30% exposure to over 9 billion barrels of oil equivalent in the Stabroek Block, and reserves are climbing thanks to new discoveries. Its breakeven cost in the play ranges from $25 to $35 per barrel of Brent Crude, so with current prices above $70, new production coming online could help boost earnings nicely over the next few years.</p>\n<p>Anoffshore energy projectsplayer, Oceaneering Int'l could see demand for its remotely-operated vehicles (ROVs), subsea project management, and manufactured products, such as umbilicals, increase nicely if offshore activity picks up because of higher per barrel prices. In Q1, ROV fleet utilization was just 53%, yet day rates improved 7% quarter over quarter, and for the full year, management expects fleet utilization to be in thehigh 50%range. With a project in Angola supported project management revenue this year, a potential uptick in book-to-bill for manufactured products, and increasing ROV utilization, it could still be early innings for the company's turnaround.</p>\n<p>There are plenty of ideas outside healthcare and energy, too. For example, nearly 50 technology stocks made our best list, despite the sector scoring below average in our sector ranking, including Microsoft (MSFT) and Shopify (SHOP), which benefit from increasing data in the cloud and e-commerce tailwinds, respectively. Amazon.com (AMZN) is also top-scoring, benefiting from growing e-commerce share of total retail sales and Prime Day, which could add over $10 billion in revenue this year, based on2020's performance.</p>\n<p>Our best list also includes a slate of services stocks, including Stitch Fix (SFIX) and Revolve Group (RVLV). As younger workers refresh wardrobes because post-vaccination, return to office trends, those companies could see a healthy uptake in sales.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Fed Has Spoken: Stocks To Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Fed Has Spoken: Stocks To Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 16:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4435924-the-fed-has-spoken-stocks-to-buy-now><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nThe Fed could begin raising rates sooner than 2023.\nHealthcare and utilities are climbing our sector ranking.\nThe top stocks in our universe today.\n\nAs I wrote last week,inflation is here. ...</p>\n\n<a href=\"https://seekingalpha.com/article/4435924-the-fed-has-spoken-stocks-to-buy-now\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"HES":"赫斯","AMZN":"亚马逊","ABBV":"艾伯维公司","BMY":"施贵宝","MSFT":"微软","SHOP":"Shopify Inc","XOM":"埃克森美孚","RVLV":"Revolve Group, LLC","OII":"国际海洋工程","SFIX":"Stitch Fix Inc."},"source_url":"https://seekingalpha.com/article/4435924-the-fed-has-spoken-stocks-to-buy-now","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1124495234","content_text":"Summary\n\nThe Fed could begin raising rates sooner than 2023.\nHealthcare and utilities are climbing our sector ranking.\nThe top stocks in our universe today.\n\nAs I wrote last week,inflation is here. Earlier this week, the Federal Reserve's Federal Open Market Committee made its most significant hawkish shift yet, accelerating its timeline for hiking the Federal Funds rate to 2023 from 2024 and setting the table to end asset repurchases as soon as this year.\nThe Central Bank left little doubt government's one-two monetary and fiscal punch has reinvigorated economic activity. Exiting the meeting, bankers believe gross domestic product, or GDP, willgrow 7%this year, up from its 6.5% forecast in March, resulting in core inflation of 3%, up from its prior outlook for 2.2%.\nHistorically, the Federal Reserve has a reputation for under estimating inflationary pressure, forcing it to act more quickly and aggressively than it originally signals. Whether this means the Fed is behind the inflationary curve now is anyone's guess, but if it is, then we may see an even more hawkish tone over the coming year.\nFor now, the Federal Reserve's stance has sparked a tug-of-war between those arguing rate hikes are too far off in the future to worry of a slowdown and those believing the Fed's timeline is still too optimistic. The knee-jerk reaction to its announcement was to buy speculative stocks, including technology, and sell mid-cycle stocks, such as energy. Further confusing the matter, late-cycle baskets, including healthcare and utilities, made the biggest move up in our large-cap sector ranking this week (see below), suggesting we may be closer to an economic reckoning than originally thought.\nThe best sectors today\nWeekly, we rank 1,600 institutional-quality stocks across seven factors. In short, our scoring system incorporates earnings growth, earnings beats, insider buying, short- and long-term money flows, days to cover held short, trends in valuation, and seasonality.\nOnce stocks run our gauntlet, we aggregate individual scores by sector to gain insight into the best baskets to over- or under-weight.\nPreviously, I've written abouttechnology's relative weaknessin our ranking. The sector still scores below our average universe score, despite catching bids earlier this week. It will be interesting to see if this week's buying spree continues, helping technology climb our ranking, especially since technology doesn't normally score below average for long. For now, staying industry and stock specific in technology still appears to be the best bet.\nSource: Top Stocks for Tomorrow.\nWe also break out our sector scores by market cap every week.\nOften, sectors move up or down in our large-cap ranking sooner than they do in mid cap or small cap; giving investors an early signal of shifting tides. For this reason, paying close attention to the large cap ranking can pay off even if you invest in smaller companies.\nThis week, both healthcare and utilities moved up in our large-cap ranking. The improvement could reflect growing clarity into the groups because of the Supreme Court's decision to keep the Affordable Care Act in place and energy strains in Texas, California, and elsewhere, respectively. Perhaps, the move up in these baskets, which are relatively inelastic to economic activity, signals the first Fed Funds rate hike will happen in 2022, not 2023, though.\nOverall, REITs, healthcare, energy, utilities, and financials are top rated in large cap, while technology, consumer goods, and basics score below average. In mid cap, energy, REITs, utilities, and consumer goods are best, while technology, industrials, basics, and healthcare are low scoring. The top small cap sectors are REITs, energy, financials, and services and the lowest-scoring baskets are healthcare, technology, and basics. Focusing on stocks in top-scoring sectors and staying selective in low-scoring sectors could be the best way to find alpha from here.\nSource: Top Stocks for Tomorrow.\nThe strongest scoring stocks to buy\nAs I mentioned, we score stocks in our universe weekly, allowing us to rank them from best to worst by screening criteria, such as market cap and sector. For example, the following stock ideas come from our weekly report highlighting the highest-scoring stocks in our universe by sector, regardless of market cap.\nOver 200 stocks made the cut for this report, including the following nine stocks.\nFirst up, investors ought to think about pharmaceutical stocks given large-cap healthcare is improving in our sector work. Over 20 healthcare stocks made our best stocks list this week, including AbbVie(NYSE:ABBV)and Bristol-Myers Squibb (BMY).\nIn the U.S., AbbVie faces-off against generic versions of its mega-blockbuster immunology drug, Humira, in 2023, but up-and-coming top sellers, including Rinvoq and Skyrizi, should helpinsulate it against a drop-off in sales. Botox also provides a nice revenue tailwind because aesthetics demand isalready above pre-COVID levelsthanks to post-vaccination doctor visits. Moonshot-style data is coming soon, too, with trial results in Alzheimer's anticipated this summer and pivotal results from Vraylar's major depressive disorder trials later this year. Finally, since it's paying down debt and still guiding for high single-digit sales growth from 2025 to 2029, despite Humira's loss of exclusivity, its 4.5% dividend appears to be on solid ground.\nImproving post-vaccination trends may make it time to watch Bristol-Myers, too. It's heavily exposed to cancer indications through it's top-selling Opdivo and Yervoy, and earlier this month, managementsaidCOVID-era, double-digit declines in new patient starts for oncology drugs improved to a 5% to 10% decline. If trends continue improving, then oncology drug demand could be back to a pre-COVID levels soon. Similarly, rebounding doctor visits also support sales of Bristol-Myers' Eliquis, a blockbuster oral anticoagulant used in cardiovascular disease.\nOutside of healthcare, energy stocks could make sense given increasing global GDP and inflation forecasts. Oil stocks sold off following the Fed's update last week, however, measured production growth should help keep per barrel prices high at E&P companies, including Hess Corp (HES), while also providing demand tailwinds for services providers, including Oceaneering International (OII).\nHess Corp'scollaborationoffshore Guyana with Exxon Mobil (XOM) gives it 30% exposure to over 9 billion barrels of oil equivalent in the Stabroek Block, and reserves are climbing thanks to new discoveries. Its breakeven cost in the play ranges from $25 to $35 per barrel of Brent Crude, so with current prices above $70, new production coming online could help boost earnings nicely over the next few years.\nAnoffshore energy projectsplayer, Oceaneering Int'l could see demand for its remotely-operated vehicles (ROVs), subsea project management, and manufactured products, such as umbilicals, increase nicely if offshore activity picks up because of higher per barrel prices. In Q1, ROV fleet utilization was just 53%, yet day rates improved 7% quarter over quarter, and for the full year, management expects fleet utilization to be in thehigh 50%range. With a project in Angola supported project management revenue this year, a potential uptick in book-to-bill for manufactured products, and increasing ROV utilization, it could still be early innings for the company's turnaround.\nThere are plenty of ideas outside healthcare and energy, too. For example, nearly 50 technology stocks made our best list, despite the sector scoring below average in our sector ranking, including Microsoft (MSFT) and Shopify (SHOP), which benefit from increasing data in the cloud and e-commerce tailwinds, respectively. Amazon.com (AMZN) is also top-scoring, benefiting from growing e-commerce share of total retail sales and Prime Day, which could add over $10 billion in revenue this year, based on2020's performance.\nOur best list also includes a slate of services stocks, including Stitch Fix (SFIX) and Revolve Group (RVLV). As younger workers refresh wardrobes because post-vaccination, return to office trends, those companies could see a healthy uptake in sales.","news_type":1},"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129318394,"gmtCreate":1624358784918,"gmtModify":1634007343223,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Xrp to the moon","listText":"Xrp to the moon","text":"Xrp to the moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129318394","repostId":"1186919064","repostType":4,"isVote":1,"tweetType":1,"viewCount":146,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129313243,"gmtCreate":1624358668682,"gmtModify":1634007344608,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Lklpx","listText":"Lklpx","text":"Lklpx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129313243","repostId":"2145056554","repostType":4,"repost":{"id":"2145056554","pubTimestamp":1624356900,"share":"https://www.laohu8.com/m/news/2145056554?lang=&edition=full","pubTime":"2021-06-22 18:15","market":"us","language":"en","title":"These 3 Dow Stocks Are Set to Soar in 2021's Second Half","url":"https://stock-news.laohu8.com/highlight/detail?id=2145056554","media":"Motley Fool","summary":"Here are the companies investors are most excited about -- and why.","content":"<p>The <b>Dow Jones Industrial Average </b>(DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.</p>\n<p>Yet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.</p>\n<h3>UnitedHealth: 34% upside</h3>\n<p><b>UnitedHealth Group </b>(NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.</p>\n<p>Yet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.</p>\n<p>UnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.</p>\n<p>Indeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.</p>\n<p><img src=\"https://static.tigerbbs.com/ffe66b7aafd67e07dd42007f2b60d638\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p>Yet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.</p>\n<h3>Goldman Sachs: 36% upside</h3>\n<p>Wall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank <b>Goldman Sachs </b>(NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.</p>\n<p>On <a href=\"https://laohu8.com/S/AONE\">one</a> hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.</p>\n<p>On the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&amp;A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&amp;A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.</p>\n<h3>Apple: 42% upside</h3>\n<p>Lastly, <b>Apple </b>(NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.</p>\n<p>Apple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.</p>\n<p>Many fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.</p>\n<h3>Further to run?</h3>\n<p>Even with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 3 Dow Stocks Are Set to Soar in 2021's Second Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 3 Dow Stocks Are Set to Soar in 2021's Second Half\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 18:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛","09086":"华夏纳指-U","AAPL":"苹果","03086":"华夏纳指","UNH":"联合健康"},"source_url":"https://www.fool.com/investing/2021/06/22/these-3-dow-stocks-set-to-soar-2021s-second-half/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145056554","content_text":"The Dow Jones Industrial Average (DJINDICES:^DJI) has had a solid year so far in 2021. Gains of 9% might not seem like all that much compared to the double-digit percentage gains we've seen in past years. But given everything that's happening in the economy, it's not surprising to see investors rein in their expectations somewhat on some of the top-performing stocks in the market.\nYet even with the gains the overall market has seen, there are still some Dow stocks that haven't climbed as far as they might. In particular, analysts looking at three stocks among the Dow Jones Industrials see the potential for substantial gains in the second half of 2021 and beyond. Below, we'll look at these three companies to see what it'll take for them to produce the big returns that investors want right now.\nUnitedHealth: 34% upside\nUnitedHealth Group (NYSE:UNH) has already put in a reasonable performance in the Dow so far this year. The health insurance giant's stock is up about 11% year to date, outpacing the broader average very slightly.\nYet investors see a lot more upside for the healthcare giant. The top price target among Wall Street analysts for UnitedHealth is $522 per share, which implies roughly a 34% gain from current levels.\nUnitedHealth has done an excellent job of navigating the ever-changing landscape of the healthcare and health insurance industries. As the largest health insurance company in the world, UnitedHealth offers coverage not just for private businesses but also for those eligible for government programs like Medicare and Medicaid.\nIndeed, UnitedHealth's handling of plans under the Affordable Care Act has been masterful, with the company having participated in the program better known as Obamacare while not overcommitting to it. With the Supreme Court having recently upheld the validity of the Affordable Care Act, UnitedHealth finds itself in a strong position to keep benefiting from its mix of business.\n\nImage source: Getty Images.\nYet many overlook the value of UnitedHealth's Optum health services unit. By aiming to help providers encourage health and wellness, Optum generates higher-margin revenue while often producing better outcomes for patients and members. With both growth drivers pushing the company forward, UnitedHealth looks well poised to keep climbing.\nGoldman Sachs: 36% upside\nWall Street has enjoyed the bull market in stocks, and that's been a blessing for investment bank Goldman Sachs (NYSE:GS). The perennial financial giant has seen its stock rise 34% so far in 2021 after less impressive performance during 2020.\nOn one hand, Goldman has reflected the broader performance of financial stocks across the market. Interest rates have generally been on the rise, and that's bolstered the prospects for more net-interest income from retail banking operations. Goldman lags behind its big-bank peers on the consumer banking front, but its relatively new Marcus unit has done a good job of attracting capital thus far.\nOn the other hand, Goldman continues to rely on its investment banking operations, and strong activity levels among initial public offerings and mergers and acquisitions (M&A) have fed the company's coffers nicely. Financing remains relatively easy to get, and that could spur more M&A activity that in turn could keep growing revenue for Goldman's investment banking division. Add to that possible tailwinds from macroeconomic factors, and it is in a solid position to climb as high as the $484 per share that represents the top price target among those following the financial stock.\nApple: 42% upside\nLastly, Apple (NASDAQ:AAPL) rounds out this list. Recently fetching $130 per share, some see the iPhone maker's stock climbing to $185. That'd be a 42% jump to help Apple recover from its 2% loss so far in 2021.\nApple's gains have continued to impress. Revenue jumped 54% in its most recent quarter, with sales of the iPhone 12 and various other products and accessories continuing to drive sales for the company. Returning capital to shareholders via dividends and stock buybacks has had a substantial impact on financial performance, especially with the number of outstanding shares having plunged by roughly 35% in just the past decade.\nMany fear that Apple hasn't generated the innovative product lines that drove its success in the mid-2000s. However, at least for now, consumers seem content with iterations on existing product lines, and as long as that remains a successful strategy, further gains for the stock seem realistic.\nFurther to run?\nEven with solid gains for the Dow in 2021, the long-term trajectory for stocks remains upward. That's a big part of why Apple, Goldman Sachs, and UnitedHealth Group look as promising as they do. Smart investors should at least keep an eye on these three stocks to see if they can live up to their full potential.","news_type":1},"isVote":1,"tweetType":1,"viewCount":266,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129319496,"gmtCreate":1624358602515,"gmtModify":1634007345323,"author":{"id":"3586344416928957","authorId":"3586344416928957","name":"6c14f57b","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586344416928957","authorIdStr":"3586344416928957"},"themes":[],"htmlText":"Hi! I truly xrp to the moon and i am allIn what about you?","listText":"Hi! I truly xrp to the moon and i am allIn what about you?","text":"Hi! I truly xrp to the moon and i am allIn what about you?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129319496","isVote":1,"tweetType":1,"viewCount":220,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}